2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
A26 / P26
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 1
Publication Date: April 7, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair–deficient or microsatellite instability–high primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Organization / Company:
1Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA;2Chernihiv Medical Center of Modern Oncology, Chernihiv Regional Council, Chernihiv, Ukraine; 3Division of Gynecologic Oncology, Research Institute, McGill University Health Centre, Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada; 4Department of Gynecologic Oncology, Uppsala University Hospital, Uppsala, Sweden, and Nordic Society of Gynecologic Oncology (NSGO), Uppsala, Sweden; 5Arizona Center for Cancer Care, Phoenix, AZ, USA; 6Willis-Knighton Cancer Center, Willis-Knighton Health System, Gynecologic Oncology Associates, Shreveport, LA, USA; 7Department of Oncology, Ospedale Vito Fazzi, Lecce, Italy; 8Department of Obstetrics/Gynecology, AMITA Health Adventist Medical Center, Hinsdale, IL, USA; 9AGO Study Group, Wiesbaden, and Oberschwabenklinik, St. Elisabethen-Klinikum, Ravensburg, Germany; 10Indiana University Health & Simon Cancer Center, Indianapolis, IN, USA; 11Department of Medical-Oncology, Catharina Hospital, Eindhoven, the Netherlands; 12Women and Infants Hospital of Rhode Island, Providence, RI, USA; 13Department of Gynecologic Oncology, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, USA; 14St. Joseph’s/Candler Gynecologic Oncology & Surgical Specialists, Candler Hospital, Savannah, GA, USA; 15Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, Washington University in St Louis, St Louis, MO, USA; 16Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; 17GSK, London, UK; 18GSK, Collegeville, PA, USA; 19Hanjani Institute for Gynecologic Oncology, Jefferson Abington Hospital, Willow Grove, PA, USA; 20Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, and NSGO, Copenhagen, Denmark
NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 1):abstr 26.
Share
Background:
In Part 1 of the phase 3 RUBY trial (NCT0-3981796), dostarlimab+carboplatin-paclitaxel (CP) demonstrated statistically significant and clinically meaningful improvements in progression- free (PFS) and overall survival (OS) compared with CP alone among patients with primary advanced or recurrent endometrial cancer (pA/R EC). Here, we report updated efficacy and safety data with 4 years of follow-up in patients with mismatch repair-deficient/microsatellite instability-high (dMMR/ MSI-H) pA/R EC. In addition, complementary conditional survival analyses (cOS/cPFS) are presented to provide clinically relevant, prognostic insights into long-term survival potential for patient counseling.
Objectives:
- Describe long-term progression-free survival and overall survival in patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in Part 1 of the RUBY trial.
- Describe the probability of long-term survival using conditional overall survival, a tool that may aid clinicians in counseling patients on their likelihood of long-term survival in the era of immunotherapy in endometrial cancer.
Methods:
Patients were randomized 1:1 to receive dostarlimab+ CP (n=53) or placebo+CP (n=65) every 3 weeks every 3 weeks (Q3W) (6 cycles) followed by dostarlimab or placebo monotherapy Q6W for up to 3 years or until disease progression. At median follow-up of 55.6 months, descriptive analyses of OS and PFS and post-hoc analyses of cOS and cPFS were conducted in the dMMR/MSI-H pA/R EC population.
Results:
Dostarlimab+CP demonstrated sustained OS (hazard ratio (HR), 0.34) and PFS (HR, 0.30) benefits at the 4-year analysis versus (vs) placebo+CP; only 4 additional progression events occurred during 2.5 years of additional follow-up since the first interim analysis. Four-year PFS rates of 57.9% vs 15.7% were consistent with reported 2-year PFS rates of 61.4% vs 15.7% for dostarlimab+CP vs placebo+ CP, respectively. Median OS was not reached (NR) at 4 years for dostarlimab+CP arm vs 32.8 months for placebo+CP; dostarlimab+CP resulted in a 4-year OS rate of 72.8% vs 40.3% for placebo+CP. Median duration of response (DOR) was NR for dostarlimab+CP and 4.8mo for placebo+CP; 4-year DOR rate was 54.8% for dostarlimab+ CP and 10.6% for placebo+CP. cOS analyses revealed the probability of remaining alive for an additional year increased with each subsequent year of survival. Patients alive and progression-free at 1-year had an almost 97% probability of remaining progression-free at 3 years (additional 2 years). Similar trends were observed at 2-year and 3-year cOS and at 2-year cPFS. No new safety signals were observed with additional follow-up.
Conclusions:
Substantial and unprecedented long-term survival benefits were demonstrated with dostarlimab+CP vs placebo+CP in patients with dMMR/MSI-H pA/R EC at 4 years. Dostarlimab+CP remains the only combination of immunotherapy and chemotherapy to demonstrate statistically significant and clinically meaningful OS benefits. Conditional survival estimates indicated that nearly all patients who remained alive and progression-free with dostarlimab+CP at 1 year remained so at 3 years, providing a powerful tool for patient counseling. Together, these data reinforce the use of dostarlimab+CP as standard-of-care and offer the potential for curative intent for patients with pA/R dMMR/MSI-H EC.
Funding: GSK.
Prior Presentations:
Presented at the Society of Gynecological Oncology (SGO) Annual Meeting on Women’s Cancer 2026, April 10–13, San Jaun, Puerto Rico.
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields
Was this page
helpful?
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields